|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind randomised multicentre trial显示文摘 | Smolen JS Kalden JR Scott DL | | 0，，： | 3 |
| 2 | Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease显示文摘 | Stefan Kiechl Georg Schett Gregor Wenning Kurt Redlich Martin Oberhollenzer Agnes Mayr Peter Santer Josef Smolen Werner Poewe Johann Willeit | 2004 | Circulation: Journal of the American Heart Association2004，，18： | 2 |
| 3 | Advances in anti- inflammatory therapy显示文摘 | Aletaha D Smolen JS | 2002 | Acta Med Austriaca2002，29，1： | 1 |
| 4 | Therapeutic strategies in early rheumatoid art hritis 显示文摘 | Smolen JS Aletaha D Machold KP | 2005 | Best Praet Res Clin R heumatol2005，19，1： | 1 |
| 5 | ICF core sets:how to specify impairment and function in systemic Lupus erythematosus显示文摘 | Aringer M Stamm TA Pisetsky DS Yarboro CH Cieza A Smolen JS | 2006 | Lupus2006，15，： | 1 |
| 6 | EULAR recom- mendations for the management of rheumatoid arthritis with syn-thetic and biological disease-modifying antirheumatic drugs 显示文摘 | Smolen JS Landewe R Breedveld FC | 2010 | Ann Rheum Dis2010，69，6： | 1 |
| 7 | Infliximab:12 years of experience显示文摘 | Smolen JS Emery P | | 0，，1： | 1 |
| 8 | Frequency selectivity, multistability, and oscillations emerge from models ofgenetic regulatory systems显示文摘 | SMOLEN P BAXTER D A BYRNE J H | 1998 | Amer J Phys1998，274，： | 1 |
| 9 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs显示文摘 | Smolen JS | 2010 | Ann Rheum Dis2010，69，6： | 1 |
| 10 | Treating rheumatoid arthritis to target: recommendations of an international task force 显示文摘 | Smolen JS Braun J Dougados M | 2010 | Ann Rheum Dis2010，69，4： | 1 |
| 11 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind,randomised,multicentre trial显示文摘 | Smolen JS Kalden JR Scott DL | 1999 | Lancet1999，353，23： | 1 |
| 12 | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis(OPTION study):a double-blind,placebo-controlled,randomised trial显示文摘 | Smolen JS Beaulieu A Rubbert-Ruth A | 2008 | Lancet2008，371，9617： | 1 |
| 13 | Mathematical modeling of gene networks review显示文摘 | Smolen P Baxter D A Byme J H | 2000 | Neuron2000，26，： | 1 |
| 14 | Novel autoantibodies for the diagnosis of rheumatol arthritis显示文摘 | Steiner G Smolen JS | 2002 | J Rheamatol2002，61，6： | 1 |
| 15 | Activation,differential localization and regulation of the stress-activated protein kinases,extracellular signal-regulated kinase,c-Jun N-terminal kinase,and P38 mitogen-activated protein kinase,in synovial tissue and cells in rheumatoid arthritis显示文摘 | Schett G Tohidast-Akrad M Smolen JS | 2000 | Arthritis Rheum2000，43，11： | 1 |
| 16 | Self- care agency and quality of life among a- dults diagnosed with inflammatory lx:wel diseases显示文摘 | Smolen DM Topp R | 2001 | Quality of Life Research2001，10，4： | 1 |
| 17 | Transforming properties of YAP,a candidate oncogene on the chromosome 11 q22 amplicon显示文摘 | Overholtzer M Zhang J Smolen GA | | 0，，： | 1 |
| 18 | Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752显示文摘 | Smolen GA Sordella R Muir B | | 0，，： | 1 |
| 19 | European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies显示文摘 | Gossec L Smolen JS Gaujoux-Viala C | 2012 | Ann Rheum Dis2012，71，1： | 1 |
| 20 | The role of tumor necrosis factor-al- pha in systemic lupus erythematosus显示文摘 | Aringer M Smolen JS | 2008 | Arthritis Res Ther2008，10，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员